Redeye was negatively surprised by the lower-than-expected sales in the quarter. The gross margin was low due to product/customer mix. We have revised our sales assumptions for 2024/2025e. While also lowering the gross margin. The underlying market in Europe is still hesitant to make investments, even if there are some small positive signals. The timing for a market turnaround is uncertain. Given the estimated changes, we have decreased our Base case to SEK 41 (44) per share.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/